That is 0 articles you have read today.
The Aporia is free and carries no advertising, so readers are the only
thing paying for it. If you are getting this much out of it, a small
donation is what keeps it independent.
Daily limit reached
You have read 0 articles today.
That is more than the 15 a day The Aporia gives away,
and well past what it can carry on nothing. Your allowance resets at
midnight.
There is no advertising here and nothing about you is sold, so readers
are the only thing paying for it. If the site is worth this much of
your day, it is worth a few dollars.
Everything else stays open: the
maps, the
directory and
search do
not count against this, and neither does re-opening something you have
already read today.
Impulse Dynamics presented new data from its U.S. Post-Approval Study at the Heart Failure Society of America’s 2026 Annual Scientific Meeting. The study involved 530 participants across 71 sites and showed that CCM® Therapy reduced heart failure hospitalizations and improved various health measures, such as biomarkers, medication use, functional status, and quality of life over one year.
Written locally by qwen2.5:14b on 2026-10-12,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Story summary
Impulse Dynamics®, a global medical device company based in MARLTON, announced at the Heart Failure Society of America (HFSA) 2026 Annual Scientific Meeting on October 12, 2026 that their CCM® Therapy has shown significant benefits for patients with heart failure. The U.S. Post-Approval Study involved 530 participants across 71 sites, evaluating the long-term safety and clinical outcomes of CCM® Therapy as approved by the FDA. Results indicated reduced heart failure hospitalizations and improved patient quality of life, supporting the broader use of this therapy for heart failure patients.
Written for “Heart Failure Treatment Data Presenta…” on 2026-10-12,
grounded in this article and the 0 other(s) covering the same event.
Why this leaning score
This article does not take a side on a contested political
question, so it has no leaning score. That is an
answer rather than a gap: a match report or a rescue can be warmly
or critically written without being left or right, and scoring it
anyway is how approval of a subject gets recorded as a political
position.
No political leaning scored for article 74473 · logged 2026-10-12
Impulse Dynamics®, a global medical device company dedicated to improving the lives of people with heart failure (HF), today announced late-breaking, one-year clinical outcomes from its U.S. Post-Approval Study of CCM® Therapy presented at the Heart Failure Society of America (HFSA) 2026 Annual Scientific Meeting.
asserted
Dynamics → dedicate → Meeting
The Post-Approval Study was a prospective, multicenter, long-term observational study approved by the FDA to evaluate long-term safety and clinical outcomes of CCM® Therapy.
asserted
Study → approve → Therapy
This analysis included 530 participants across 71 sites.
asserted
analysis → include → sites
The findings add to a growing body of clinical and research evidence for supporting the use of CCM®Therapy and demonstrate meaningful improvements across multiple HF measures, including heart failure hospitalization, biomarkers, medication utilization, functional status and quality of life.
asserted
findings → add → life
The Aporia
